Neurocess closes €4M pre-Series A for EEG Alzheimer's screening pilot in Netherlands primary care
Summary
Amsterdam-based Neurocess raised €4M pre-Series A from Forbion and Inkef Capital to fund a 1,000-patient pilot of their AI EEG Alzheimer's screening platform in Dutch primary care centers. The pilot, running across 15 GP practices in Amsterdam and Rotterdam, will generate the real-world clinical utility data needed to support reimbursement applications in the Netherlands and Germany.
Why it matters
Primary care Alzheimer's screening via a 20-minute EEG is exactly what the healthcare system needs — cheap, scalable, and actionable before patients develop dementia symptoms. A successful Dutch primary care pilot creates a replicable model for European market entry with built-in HTA evidence.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial